Key result
Incorporating novel biomarkers into multi-biomarker strategies improves post-MI risk stratification and prognosis.
Why the study?
Despite advances in diagnosis and treatment, acute myocardial infarction remains a leading cause of morbidity and mortality, requiring early identification of high-risk patients through biomarker measurement to improve risk stratification and guide individualized therapy.
Do cardiac biomarkers and artificial intelligence algorithms improve risk stratification and prognostic assessment in patients with acute myocardial infarction?
Do cardiac biomarkers and artificial intelligence algorithms improve risk stratification and prognostic assessment in patients with acute myocardial infarction?
Multi-biomarker strategies and artificial intelligence algorithms show promise in improving risk stratification and prognostic assessment for patients with acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
May support multi-biomarker panels for AMI risk stratification; leaves open clinical adoption pending prospective validation.
Despite all the important advances in its diagnosis and treatment, acute myocardial infarction (AMI) is still one of the most prominent causes of morbidity and mortality worldwide. Early identification of patients at high risk of poor outcomes through the measurement of various biomarker concentrations might contribute to more accurate risk stratification and help to guide more individualized therapeutic strategies, thus improving prognoses. The aim of this article is to provide an overview of the role and applications of cardiac biomarkers in risk stratification and prognostic assessment for patients with myocardial infarction. Although there is no ideal biomarker that can provide prognostic information for risk assessment in patients with AMI, the results obtained in recent years are promising. Several novel biomarkers related to the pathophysiological processes found in patients with myocardial infarction, such as inflammation, neurohormonal activation, myocardial stress, myocardial necrosis, cardiac remodeling and vasoactive processes, have been identified; they may bring additional value for AMI prognosis when included in multi-biomarker strategies. Furthermore, the use of artificial intelligence algorithms for risk stratification and prognostic assessment in these patients may have an extremely important role in improving outcomes.
No takes yet. Share an insight, caveat, or question.
Stătescu et al. (2022) studied this question. Novel biomarkers related to myocardial infarction pathophysiology can enhance risk stratification and prognosis when used in multi-biomarker strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: